Chemical: Drug

streptomycin

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for streptomycin

	Gene ?	Variant? (147)	Alternate Names ?	Chemicals ?	Alleles ? (+ chr strand)	Function ?	Amino Acid? Translation
CA	GSTM1	non-null		Drugs For Treatment Of Tuberculosis ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA VA	GSTM1	null		Drugs For Treatment Of Tuberculosis ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA	GSTT1	non-null		Drugs For Treatment Of Tuberculosis ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA VA	GSTT1	null		Drugs For Treatment Of Tuberculosis ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*4		ethambutol isoniazid rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*5		ethambutol isoniazid rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*5B		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*6		ethambutol isoniazid rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*6A		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*7		ethambutol isoniazid rifampin streptomycin	N/A	N/A	N/A
VA	NAT2	*7A		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA VA	STAT3	CTA		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA VA	STAT3	TCG		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
CA VA	STAT3	TTA		ethambutol isoniazid pyrazinamide rifampin streptomycin	N/A	N/A	N/A
VA		rs1524107	NC_000007.13:g.22768219C>T, NC_000007.14:g.22728600C>T, NG_011640.1:g.6454C>T, NM_000600.4:c.211-93C>T, NM_001318095.1:c.-18-93C>T, NR_131935.1:n.-980G>A, XM_005249745.1:c.373-93C>T, XM_005249745.3:c.373-93C>T, XM_005249746.1:c.-18-93C>T, XM_011515390.1:c.211-93C>T, XM_011515391.1:c.-18-93C>T	isoniazid pyrazinamide ethambutol rifampin streptomycin	C > T	SNP
VA	GSTP1	rs1695	NC_000011.10:g.67585218A>G, NC_000011.9:g.67352689A>G, NG_012075.1:g.6624A>G, NM_000852.3:c.313A>G, NP_000843.1:p.Ile105Val, XM_005273958.1:c.313A>G, XP_005274015.1:p.Ile105Val, rs1138257, rs11553891, rs17353321, rs17856342, rs2230827, rs4609, rs56971933, rs947894	isoniazid pyrazinamide ethambutol rifampin streptomycin	A > G	SNP	I105V
VA	CYP2E1	rs2031920	NC_000010.10:g.135339845C>T, NC_000010.11:g.133526341C>T, NG_008383.1:g.3979C>T, NM_000773.3:c.-1055C>T, XM_005252665.1:c.-512C>T, rs3813868	isoniazid pyrazinamide ethambutol rifampin streptomycin	C > T	SNP
VA	IL6	rs2066992	NC_000007.13:g.22768249G>T, NC_000007.14:g.22728630G>T, NG_011640.1:g.6484G>T, NM_000600.4:c.211-63G>T, NM_001318095.1:c.-18-63G>T, NR_131935.1:n.-1010C>A, XM_005249745.1:c.373-63G>T, XM_005249745.3:c.373-63G>T, XM_005249746.1:c.-18-63G>T, XM_011515390.1:c.211-63G>T, XM_011515391.1:c.-18-63G>T, rs17147236, rs58064907	isoniazid pyrazinamide ethambutol rifampin streptomycin	G > T	SNP
VA	IL6	rs2069837	NC_000007.13:g.22768027A>G, NC_000007.14:g.22728408A>G, NG_011640.1:g.6262A>G, NM_000600.4:c.211-285A>G, NM_001318095.1:c.-18-285A>G, NR_131935.1:n.-788T>C, XM_005249745.1:c.373-285A>G, XM_005249745.3:c.373-285A>G, XM_005249746.1:c.-18-285A>G, XM_011515390.1:c.211-285A>G, XM_011515391.1:c.-18-285A>G, rs111176548, rs16873259, rs3779040, rs56908115	isoniazid pyrazinamide ethambutol rifampin streptomycin	A > G	SNP
VA	HSPA1L	rs2227956	NC_000006.11:g.31778272G=, NC_000006.11:g.31778272G>A, NC_000006.12:g.31810495G=, NC_000006.12:g.31810495G>A, NG_011855.1:g.9564C=, NG_011855.1:g.9564C>T, NM_005527.3:c.1478C=, NM_005527.3:c.1478C>T, NP_005518.3:p.Thr493=, NP_005518.3:p.Thr493Met, NT_113891.2:g.3287853A=, NT_113891.2:g.3287853A>G, NT_113891.3:g.3287747A=, NT_113891.3:g.3287747A>G, NT_167244.1:g.3093033A=, NT_167244.1:g.3093033A>G, NT_167244.2:g.3143117A=, NT_167244.2:g.3143117A>G, NT_167245.1:g.3063859G=, NT_167245.1:g.3063859G>A, NT_167245.2:g.3058274G=, NT_167245.2:g.3058274G>A, NT_167248.1:g.3071920A=, NT_167248.1:g.3071920A>G, NT_167248.2:g.3066324A=, NT_167248.2:g.3066324A>G, XM_005249070.1:c.1670C=, XM_005249070.1:c.1670C>T, XM_005249070.3:c.1670C=, XM_005249070.3:c.1670C>T, XM_005249071.1:c.1478C=, XM_005249071.1:c.1478C>T, XM_005249072.1:c.1478C=, XM_005249072.1:c.1478C>T, XM_005249073.1:c.1478C=, XM_005249073.1:c.1478C>T, XM_005249073.2:c.1478C=, XM_005249073.2:c.1478C>T, XM_005249074.1:c.1478C=, XM_005249074.1:c.1478C>T, XM_005272813.1:c.1670T=, XM_005272813.1:c.1670T>C, XM_005272814.1:c.1478T=, XM_005272814.1:c.1478T>C, XM_005272815.1:c.1478T=, XM_005272815.1:c.1478T>C, XM_005272816.1:c.1478T=, XM_005272816.1:c.1478T>C, XM_005272816.2:c.1478T=, XM_005272816.2:c.1478T>C, XM_005272817.1:c.1478T=, XM_005272817.1:c.1478T>C, XM_005274858.1:c.1478T=, XM_005274858.1:c.1478T>C, XM_005274859.1:c.1670T=, XM_005274859.1:c.1670T>C, XM_005274859.3:c.1670T=, XM_005274859.3:c.1670T>C, XM_005274860.1:c.1478T=, XM_005274860.1:c.1478T>C, XM_005274861.1:c.1478T=, XM_005274861.1:c.1478T>C, XM_005274861.2:c.1478T=, XM_005274861.2:c.1478T>C, XM_005274862.1:c.1478T=, XM_005274862.1:c.1478T>C, XM_005274970.1:c.1670C=, XM_005274970.1:c.1670C>T, XM_005274970.3:c.1670C=, XM_005274970.3:c.1670C>T, XM_005274971.1:c.1478C=, XM_005274971.1:c.1478C>T, XM_005274972.1:c.1478C=, XM_005274972.1:c.1478C>T, XM_005274973.1:c.1478C=, XM_005274973.1:c.1478C>T, XM_005274973.2:c.1478C=, XM_005274973.2:c.1478C>T, XM_005274974.1:c.1478C=, XM_005274974.1:c.1478C>T, XM_005275398.1:c.1478T=, XM_005275398.1:c.1478T>C, XM_005275399.1:c.1670T=, XM_005275399.1:c.1670T>C, XM_005275400.1:c.1478T=, XM_005275400.1:c.1478T>C, XM_005275401.1:c.1478T=, XM_005275401.1:c.1478T>C, XM_005275401.2:c.1478T=, XM_005275401.2:c.1478T>C, XM_005275402.1:c.1478T=, XM_005275402.1:c.1478T>C, XM_011514566.1:c.1478C=, XM_011514566.1:c.1478C>T, XM_011546311.1:c.1478T=, XM_011546311.1:c.1478T>C, XM_011547246.1:c.1478T=, XM_011547246.1:c.1478T>C, XM_011547247.1:c.1670T=, XM_011547247.1:c.1670T>C, XM_011547652.1:c.1478C=, XM_011547652.1:c.1478C>T, XM_011548238.1:c.1478T=, XM_011548238.1:c.1478T>C, XM_011548239.1:c.1670T=, XM_011548239.1:c.1670T>C, XP_005249127.1:p.Thr557=, XP_005249127.1:p.Thr557Met, XP_005249128.1:p.Thr493=, XP_005249128.1:p.Thr493Met, XP_005249129.1:p.Thr493=, XP_005249129.1:p.Thr493Met, XP_005249130.1:p.Thr493=, XP_005249130.1:p.Thr493Met, XP_005249131.1:p.Thr493=, XP_005249131.1:p.Thr493Met, XP_005272870.1:p.Met557=, XP_005272870.1:p.Met557Thr, XP_005272871.1:p.Met493=, XP_005272871.1:p.Met493Thr, XP_005272872.1:p.Met493=, XP_005272872.1:p.Met493Thr, XP_005272873.1:p.Met493=, XP_005272873.1:p.Met493Thr, XP_005272874.1:p.Met493=, XP_005272874.1:p.Met493Thr, XP_005274915.1:p.Met493=, XP_005274915.1:p.Met493Thr, XP_005274916.1:p.Met557=, XP_005274916.1:p.Met557Thr, XP_005274917.1:p.Met493=, XP_005274917.1:p.Met493Thr, XP_005274918.1:p.Met493=, XP_005274918.1:p.Met493Thr, XP_005274919.1:p.Met493=, XP_005274919.1:p.Met493Thr, XP_005275027.1:p.Thr557=, XP_005275027.1:p.Thr557Met, XP_005275028.1:p.Thr493=, XP_005275028.1:p.Thr493Met, XP_005275029.1:p.Thr493=, XP_005275029.1:p.Thr493Met, XP_005275030.1:p.Thr493=, XP_005275030.1:p.Thr493Met, XP_005275031.1:p.Thr493=, XP_005275031.1:p.Thr493Met, XP_005275455.1:p.Met493=, XP_005275455.1:p.Met493Thr, XP_005275456.1:p.Met557=, XP_005275456.1:p.Met557Thr, XP_005275457.1:p.Met493=, XP_005275457.1:p.Met493Thr, XP_005275458.1:p.Met493=, XP_005275458.1:p.Met493Thr, XP_005275459.1:p.Met493=, XP_005275459.1:p.Met493Thr, XP_011512868.1:p.Thr493=, XP_011512868.1:p.Thr493Met, XP_011544613.1:p.Met493=, XP_011544613.1:p.Met493Thr, XP_011545548.1:p.Met493=, XP_011545548.1:p.Met493Thr, XP_011545549.1:p.Met557=, XP_011545549.1:p.Met557Thr, XP_011545954.1:p.Thr493=, XP_011545954.1:p.Thr493Met, XP_011546540.1:p.Met493=, XP_011546540.1:p.Met493Thr, XP_011546541.1:p.Met557=, XP_011546541.1:p.Met557Thr, rs116591280, rs117465227, rs148468928, rs35842419, rs386561656, rs52829371, rs57160046	isoniazid pyrazinamide ethambutol rifampin streptomycin	G > A	SNP	T493M
CA	MT-RNR1	rs267606617		aminoglycoside antibacterials kanamycin gentamicin tobramycin neomycin streptomycin amikacin	A > G	SNP
CA	MT-RNR1	rs267606618		aminoglycoside antibacterials kanamycin gentamicin tobramycin neomycin streptomycin amikacin	T > C	SNP
CA	MT-RNR1	rs267606619		aminoglycoside antibacterials kanamycin gentamicin tobramycin neomycin streptomycin amikacin	C > T	SNP
VA	CYP1A1	rs4646903	NC_000015.10:g.74719300A>G, NC_000015.9:g.75011641A>G, NG_008431.1:g.1759A>G, NM_000499.3:c.*1189T>C, NM_000499.4:c.*1189T>C, NM_000499.4:c.*947+242T>C, NM_001319216.1:c.*1189T>C, NM_001319216.1:c.*947+242T>C, NM_001319217.1:c.*1189T>C, NM_001319217.1:c.*947+242T>C, XM_005254185.1:c.*1189T>C, XM_005254186.1:c.*1189T>C, XM_005254187.1:c.*1189T>C, XM_005254188.1:c.*1189T>C, XM_005254189.1:c.*1189T>C, rs116877783, rs17861083, rs5030838	isoniazid pyrazinamide ethambutol rifampin streptomycin	A > G A > T	SNP
VA	CYP2E1	rs6413432	NC_000010.10:g.135348544T>A, NC_000010.11:g.133535040T>A, NG_008383.1:g.12678T>A, NM_000773.3:c.967+1143T>A, XM_005252665.1:c.1027+1143T>A	isoniazid pyrazinamide ethambutol rifampin streptomycin	T > A	SNP

[ see larger image ] [ see 3D structure ]

provided by PubChem

Overview

PharmGKB Accession Id

PA451512

Type(s):

Drug

Other Vocabularies

• ATC: Antibiotics (A07AA)
• ATC: Streptomycins (J01GA)
• ATC: Antibiotics (S01AA)
• UMLS: Streptomycin (C0038425)
• RxNorm: Streptomycin (10109)
• NDFRT: STREPTOMYCIN (N0000148018)

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Absorption, Distribution, Metabolism, Elimination & Toxicity

Chemical Properties

C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O

InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1

Publications related to streptomycin: 83

CA	Allele-specific PCR for detecting the deafness-associated mitochondrial 12S rRNA mutations. Gene. 2016. Ding Yu, et al.
CA	Is deafness mutation screening required in cystic fibrosis patients?. Paediatric respiratory reviews. 2016. Abusamra Rania, et al.
CA	Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis. Journal of medical genetics. 2015. Jing Wu, et al.
CA	Audio Profiles in Mitochondrial Deafness m.1555A>G and m.3243A>G Show Distinct Differences. Medical science monitor : international medical journal of experimental and clinical research. 2015. Iwanicka-Pronicka Katarzyna, et al.
CA VA	Analysis of IL-6, STAT3 and HSPA1L Gene Polymorphisms in Anti-Tuberculosis Drug-Induced Hepatitis in a Nested Case-Control Study. PloS one. 2015. Wang Jing, et al.
VA	Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study. PloS one. 2015. He Lei, et al.
CA	Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?. International journal of pediatric otorhinolaryngology. 2014. Al-Malky Ghada, et al.
CA	Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinburgh, Scotland). 2014. Singla Neha, et al.
	Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nature genetics. 2014. Casali Nicola, et al.
CA	Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. BMC pediatrics. 2014. Göpel Wolfgang, et al.
CA	The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. Journal of clinical pharmacy and therapeutics. 2012. Monteiro T P, et al.
CA	CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. Journal of clinical pharmacy and therapeutics. 2012. Tang S-W, et al.
CA	Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Molecular diagnosis & therapy. 2012. Costa Gustavo N O, et al.
CA	Heteroplasmy levels of mtDNA1555A>G mutation is positively associated with diverse phenotypes and mutation transmission in a Chinese family. Biochemical and biophysical research communications. 2012. Shen Shan-Shan, et al.
VA	NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Annals of hepatology. 2012. Lv Xiaozhen, et al.
VA	Relationship between CYP2E1 polymorphism and increase of ALT activity during therapy of patients with pulmonary tuberculosis. Bulletin of experimental biology and medicine. 2011. Kudryashov A V, et al.
CA	Unique penetrance of hearing loss in a five-generation Chinese family with the mitochondrial 12S rRNA 1555A > G mutation. Acta oto-laryngologica. 2011. Men Meichao, et al.
CA	Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Memórias do Instituto Oswaldo Cruz. 2011. Teixeira Raquel Lima de Figueiredo, et al.
CA	The prevalence of mitochondrial mutations associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. The Laryngoscope. 2011. Ealy Megan, et al.
CA	Molecular epidemiological analysis of mitochondrial DNA12SrRNA A1555G, GJB2, and SLC26A4 mutations in sporadic outpatients with nonsyndromic sensorineural hearing loss in China. Acta oto-laryngologica. 2011. Ji Yu-bin, et al.
CA	Detection of deafness-causing mutations in the Greek mitochondrial genome. Disease markers. 2011. Kokotas Haris, et al.
CA VA	Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In vivo (Athens, Greece). 2011. Sotsuka Takayo, et al.
	Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug safety : an international journal of medical toxicology and drug experience. 2010. Youngster Ilan, et al.
CA	GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. Journal of clinical pharmacy and therapeutics. 2010. Chatterjee S, et al.
CA	Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion. 2010. Lu Jianxin, et al.
CA	Genetic mutations and aminoglycoside-induced ototoxicity in neonates. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2010. Johnson Romaine F, et al.
CA	Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochemical and biophysical research communications. 2010. Rydzanicz Małgorzata, et al.
CA	Extensive and rapid screening for major mitochondrial DNA point mutations in patients with hereditary hearing loss. Journal of human genetics. 2010. Kato Tomofumi, et al.
CA	Mitochondrial haplotypes may modulate the phenotypic manifestation of the deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion. 2010. Lu Jianxin, et al.
CA	GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinburgh, Scotland). 2010. Kim Sang-Heon, et al.
CA	Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. The Journal of international medical research. 2010. Wang T, et al.
CA	Mitochondrial haplotype and phenotype of 13 Chinese families may suggest multi-original evolution of mitochondrial C1494T mutation. Mitochondrion. 2009. Zhu Yuhua, et al.
	Drug discovery and natural products: end of an era or an endless frontier?. Science (New York, N.Y.). 2009. Li Jesse W-H, et al.
CA	Mitochondrial tRNA(Glu) A14693G variant may modulate the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in a Han Chinese family. Journal of genetics and genomics = Yi chuan xue bao. 2009. Ding Yu, et al.
CA	Mutation analysis of mitochondrial DNA 12SrRNA and tRNASer(UCN) genes in non-syndromic hearing loss patients. Mitochondrion. 2008. Konings Annelies, et al.
CA	Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenetics and genomics. 2008. Conrad Douglas J, et al.
CA	Mitochondrial tRNAThr G15927A mutation may modulate the phenotypic manifestation of ototoxic 12S rRNA A1555G mutation in four Chinese families. Pharmacogenetics and genomics. 2008. Wang Xinjian, et al.
CA	Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver international : official journal of the International Association for the Study of the Liver. 2008. Leiro Virginia, et al.
CA	Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. The Journal of toxicological sciences. 2008. Fukino Katsumi, et al.
CA	Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. Human mutation. 2008. Ballana Ester, et al.
CA	Whole mitochondrial genome screening in maternally inherited non-syndromic hearing impairment using a microarray resequencing mitochondrial DNA chip. European journal of human genetics : EJHG. 2007. Lévêque Marianne, et al.
CA	Coexistence of mitochondrial 12S rRNA C1494T and CO1/tRNA(Ser(UCN)) G7444A mutations in two Han Chinese pedigrees with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2007. Yuan Huijun, et al.
CA	Maternally inherited aminoglycoside-induced and nonsyndromic hearing loss is associated with the 12S rRNA C1494T mutation in three Han Chinese pedigrees. Gene. 2007. Chen Jianfu, et al.
CA	The mitochondrial tRNA(Ala) T5628C variant may have a modifying role in the phenotypic manifestation of the 12S rRNA C1494T mutation in a large Chinese family with hearing loss. Biochemical and biophysical research communications. 2007. Han Dongyi, et al.
	Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. The Medical journal of Malaysia. 2007. Tan W C, et al.
CA	Very low penetrance of hearing loss in seven Han Chinese pedigrees carrying the deafness-associated 12S rRNA A1555G mutation. Gene. 2007. Tang Xiaowen, et al.
CA	Molecular and clinical characterisation of three Spanish families with maternally inherited non-syndromic hearing loss caused by the 1494C->T mutation in the mitochondrial 12S rRNA gene. Journal of medical genetics. 2006. Rodríguez-Ballesteros M, et al.
CA	Variants in mitochondrial tRNAGlu, tRNAArg, and tRNAThr may influence the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in three Han Chinese families with hearing loss. American journal of medical genetics. Part A. 2006. Young Wie-Yen, et al.
CA	Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA T1095C mutation in three Chinese families. Biochemical and biophysical research communications. 2006. Dai Pu, et al.
CA	Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. Biochemical and biophysical research communications. 2006. Bravo Olga, et al.
CA	Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochemical and biophysical research communications. 2006. Ballana Ester, et al.
	Adverse reactions to first-line antituberculosis drugs. Expert opinion on drug safety. 2006. Forget Eric J, et al.
CA	Clinical and molecular analysis of a four-generation Chinese family with aminoglycoside-induced and nonsyndromic hearing loss associated with the mitochondrial 12S rRNA C1494T mutation. Biochemical and biophysical research communications. 2006. Wang Qiuju, et al.
CA	Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: implication for early detection and prevention of deafness. Biochemical and biophysical research communications. 2006. Dai Pu, et al.
CA	Clinical evaluation and mitochondrial DNA sequence analysis in two Chinese families with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2005. Zhao Lidong, et al.
CA	Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. Auris, nasus, larynx. 2005. Kobayashi Katsuhiko, et al.
CA	Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. Human genetics. 2005. Li Zhiyuan, et al.
CA	Extremely low penetrance of hearing loss in four Chinese families with the mitochondrial 12S rRNA A1555G mutation. Biochemical and biophysical research communications. 2005. Young Wie-Yen, et al.
CA	Clinical evaluation and sequence analysis of the complete mitochondrial genome of three Chinese patients with hearing impairment associated with the 12S rRNA T1095C mutation. Biochemical and biophysical research communications. 2004. Zhao Lidong, et al.
CA	Audiovestibular findings in patients with mitochondrial A1555G mutation. The Laryngoscope. 2004. Noguchi Yoshihiro, et al.
CA	Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. American journal of human genetics. 2004. Zhao Hui, et al.
CA	Cosegregation of C-insertion at position 961 with the A1555G mutation of the mitochondrial 12S rRNA gene in a large Chinese family with maternally inherited hearing loss. American journal of medical genetics. Part A. 2004. Li Ronghua, et al.
CA	Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss. Journal of medical genetics. 2003. del Castillo F J, et al.
CA	Atypical muscle pathology and a survey of cis-mutations in deaf patients harboring a 1555 A-to-G point mutation in the mitochondrial ribosomal RNA gene. Neuromuscular disorders : NMD. 2002. Yamasoba Tatsuya, et al.
CA	Mutation A1555G in the 12S rRNA gene and its epidemiological importance in German, Hungarian, and Polish patients. Human mutation. 2002. Kupka Susan, et al.
CA	Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. Journal of gastroenterology and hepatology. 2001. Roy B, et al.
CA	Maternally inherited deafness associated with a T1095C mutation in the mDNA. European journal of human genetics : EJHG. 2001. Tessa A, et al.
CA	Different clinical characteristics of aminoglycoside-induced profound deafness with and without the 1555 A-->G mitochondrial mutation. ORL; journal for oto-rhino-laryngology and its related specialties. 2001. Tono T, et al.
CA	A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Annals of neurology. 2000. Thyagarajan D, et al.
VA	Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2000. Ohno M, et al.
CA	Prevalence of mitochondrial gene mutations among hearing impaired patients. Journal of medical genetics. 2000. Usami S, et al.
CA	Aminoglycoside-induced deafness associated with the mitochondrial DNA mutation A1555G. American journal of otolaryngology. 1999. Shohat M, et al.
CA	Cochlear implantation in a patient with profound hearing loss with the A1555G mitochondrial mutation. The American journal of otology. 1998. Tono T, et al.
CA	Hearing loss due to the mitochondrial A1555G mutation in Italian families. American journal of medical genetics. 1998. Casano R A, et al.
CA	Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. American journal of human genetics. 1998. Estivill X, et al.
CA	Familial streptomycin ototoxicity in a South African family: a mitochondrial disorder. Journal of medical genetics. 1997. Gardner J C, et al.
CA	Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. The Laryngoscope. 1997. Usami S, et al.
CA	Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. Journal of medical genetics. 1997. Pandya A, et al.
CA	Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. American journal of otolaryngology. 1997. Fischel-Ghodsian N, et al.
CA	A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic acids research. 1993. Hutchin T, et al.
CA	Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nature genetics. 1993. Prezant T R, et al.
CA	Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. American journal of otolaryngology. 1993. Fischel-Ghodsian N, et al.
VA	Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. British medical journal. 1976. Chan T K, et al.

LinkOuts